Earlybird Venture Capital

Earlybird Venture Capital is one of Europe’s longer-tenured independent venture firms, with a Berlin base and an investing footprint that spans Western Europe, Eastern Europe, and Turkey. The firm has built its reputation through multi-decade activity across consumer, enterprise, and healthcare technology, and its longevity gives it pattern recognition that few European venture firms can match.

The healthcare focus runs through digital health, AI/ML in healthcare, and health IT and healthcare software. Within that, Earlybird has been active across European digital health and health software companies, with a particular willingness to engage with companies whose products target European healthcare systems and whose paths involve navigating multiple national regulatory and reimbursement environments. AI is treated as an embedded layer rather than a separate category, with attention to how machine learning capabilities translate into durable product advantages inside regulated environments.

Check sizes run from $1M to $5M, with the fund active across pre-seed, seed, Series A, Series B, and Series C rounds. That stage breadth allows Earlybird to be either a lead in early institutional rounds or a meaningful participant in follow-on rounds as portfolio companies scale across European and international markets. Founders should expect diligence focused on commercial fundamentals, market sizing, competitive positioning, and the credibility of expansion plans, alongside attention to product and technology questions.

The team is structured across multiple funds and geographies, with investors who bring operating, investing, and consulting backgrounds to portfolio companies. That structure allows Earlybird to engage meaningfully with companies whose growth requires expansion across European national markets, each of which presents its own regulatory, reimbursement, and commercial dynamics. The firm has strong relationships with European corporates, hospital systems, and follow-on capital providers, and those networks are a meaningful part of what it offers portfolio companies.

For founders, working with Earlybird means an investor that is engaged on commercial strategy and follow-on fundraising and that takes seriously the practical complexity of building European healthcare companies. Post-investment support tends to focus on go-to-market questions, hiring, syndication with both European and US co-investors, and helping companies navigate cross-border expansion. The firm is a less natural fit for companies whose primary market is the US and whose European footprint is incidental, or for founders who want a small, single-market lead. It is a strong fit for European healthcare and digital health teams whose ambitions span the region and who want an investor with the longevity, the network, and the operating experience to support a multi-year path from early product validation through international scaling. Earlybird’s working style tends to be commercially focused and pragmatic.